{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T18:47:07Z","timestamp":1769971627090,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T00:00:00Z","timestamp":1493942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s13311-017-0531-1","type":"journal-article","created":{"date-parts":[[2017,5,5]],"date-time":"2017-05-05T09:53:14Z","timestamp":1493977994000},"page":"741-749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective"],"prefix":"10.1016","volume":"14","author":[{"given":"Ben","family":"Sessa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1007\/s13311-017-0531-1_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/15374410802698396","article-title":"Insecure attachment, dysfunctional attitudes, and low self-esteem predicting prospective symptoms of depression and anxiety during adolescence","volume":"38","author":"Lee","year":"2009","journal-title":"J Clin Child Adolesc Psychol"},{"issue":"6","key":"10.1007\/s13311-017-0531-1_bib2","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/000486700265","article-title":"Down will come baby, cradle and all: diagnostic and therapeutic implications of chronic trauma on child development","volume":"34","author":"Streeck-Fischer","year":"2000","journal-title":"Aust N Z J Psychiatry 2000"},{"issue":"9","key":"10.1007\/s13311-017-0531-1_bib3","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0006-3223(00)00828-3","article-title":"Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study","volume":"47","author":"Rauch","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1007\/s13311-017-0531-1_bib4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.0963-7214.2004.00309.x","article-title":"Substance abuse and posttraumatic stress disorder","volume":"13","author":"Brady","year":"2004","journal-title":"Curr Dir Psychol Sci"},{"key":"10.1007\/s13311-017-0531-1_bib5","series-title":"The Northern Ireland Centre for Trauma and Transformation and the Psychology Research Institute","article-title":"Trauma, health and conflict in Northern Ireland: a study of the epidemiology of trauma related disorder and qualitative investigation of the impact of trauma on the individual","author":"Ferry","year":"2017"},{"key":"10.1007\/s13311-017-0531-1_bib6","series-title":"Clinical guidelines","article-title":"Post-traumatic stress disorder: the management of PTSD in adults and children in primary and secondary care","year":"2005"},{"issue":"2","key":"10.1007\/s13311-017-0531-1_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","article-title":"Pharmacotherapy for post-traumatic stress disorder: a systematic review and meta-analysis","volume":"206","author":"Hoskins","year":"2014","journal-title":"Br J Psychiatry 2015"},{"key":"10.1007\/s13311-017-0531-1_bib8","article-title":"MDMA and PTSD treatment: PTSD: From novel pathophysiology to innovative therapeutics","author":"Sessa","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-017-0531-1_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1997.tb52356.x","article-title":"Insights into the neuro-biology of impulsive behavior from serotonin receptor knockout mice","volume":"836","author":"Brunner","year":"1997","journal-title":"Ann NY Acad Sci 1997"},{"issue":"177","key":"10.1007\/s13311-017-0531-1_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0304-3940(94)90057-4","article-title":"Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors","volume":"1994","author":"Nash","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-017-0531-1_bib11","first-page":"63","article-title":"Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines","volume":"381","author":"Cozzi","year":"1999","journal-title":"Eur J Pharmacol 1999"},{"key":"10.1007\/s13311-017-0531-1_bib12","first-page":"975","article-title":"Investigation of the prejunctional alpha2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens","volume":"128","author":"Lavelle","year":"1999","journal-title":"Br J Pharmacol 1999"},{"issue":"2","key":"10.1007\/s13311-017-0531-1_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","article-title":"A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d)","volume":"146","author":"Thompson","year":"2007","journal-title":"Neuroscience"},{"issue":"4","key":"10.1007\/s13311-017-0531-1_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","article-title":"Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class: entactogens","volume":"18","author":"Nichols","year":"1986","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"10.1007\/s13311-017-0531-1_bib15","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00213-002-1131-1","article-title":"Subjective and hormonal effects of 3,4- methylenedioxymethamphetamine (MDMA) in humans","volume":"162","author":"Harris","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1007\/s13311-017-0531-1_bib16","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/scan\/nst161","article-title":"MDMA enhances emotional empathy and prosocial behavior","volume":"9","author":"Hysek","year":"2013","journal-title":"Soc Cogn Affect Neurosci"},{"key":"10.1007\/s13311-017-0531-1_bib17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0893-133X(00)00130-5","article-title":"3,4- Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans","volume":"23","author":"Gamma","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1007\/s13311-017-0531-1_bib18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00213-012-2645-9","article-title":"MDMA enhances \u201cmind reading\u201d of positive emotions and impairs \u201cmind reading\u201d of negative emotions","volume":"222","author":"Hysek","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1007\/s13311-017-0531-1_bib19","series-title":"Effective treatments for PTSD, practice guide- lines from the International Society for Traumatic Stress Studies","author":"Foa","year":"2009"},{"key":"10.1007\/s13311-017-0531-1_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/pnp.216","article-title":"Can MDMA enhance Trauma-focused psychotherapy?","volume":"15","author":"Sessa","year":"2011","journal-title":"Prog Neurol Psychiatry"},{"key":"10.1007\/s13311-017-0531-1_bib21","unstructured":"MAPS (2016) MDMA investigational brochure. Available at: http:\/\/www.maps.org\/research\/mdma\/mdma-research-timeline\/104-other-mdma-resources\/5400-mdma-investigator-s-brochure-and-fda-annual-report&Itemid=485. Accessed 13 April, 2017."},{"key":"10.1007\/s13311-017-0531-1_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1136\/bmj.326.7380.80","article-title":"Review of deaths related to taking ecstasy, England and Wales, 1997\u20132000","volume":"326","author":"Schifano","year":"2003","journal-title":"BMJ"},{"key":"10.1007\/s13311-017-0531-1_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2044.1993.tb07423.x","article-title":"Drug- induced hyperthermia","volume":"48","author":"Nimmo","year":"1993","journal-title":"Anaesthesia"},{"issue":"3","key":"10.1007\/s13311-017-0531-1_bib24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/0269881106061514","article-title":"Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population","volume":"20","author":"Wolff","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0531-1_bib25","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1523\/JNEUROSCI.18-13-05086.1998","article-title":"Small changes in ambient temperature causes large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat","volume":"18","author":"Malberg","year":"1998","journal-title":"J Neuroscience"},{"key":"10.1007\/s13311-017-0531-1_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/0269881107084738","article-title":"MDMA, politics and medical research: Have we thrown the baby out with the bathwater?","volume":"21","author":"Sessa","year":"2007","journal-title":"J Psychopharmacol"},{"issue":"7","key":"10.1007\/s13311-017-0531-1_bib27","first-page":"821","article-title":"Mood and cognitive effects of \u00b13,4--methylenedioxymethamphetamine (MDMA, \u2018ecstasy'): week-end \u2018high' followed by mid-week low","volume":"92","author":"Curran","year":"1997","journal-title":"Addiction 1997"},{"issue":"1","key":"10.1007\/s13311-017-0531-1_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/0269881112463467","article-title":"Subacute effects of ecstasy on mood: an exploration of associated risk factors","volume":"27","author":"Scott","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1007\/s13311-017-0531-1_bib29","first-page":"175","article-title":"An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users","volume":"24","author":"Pirona","year":"2010","journal-title":"J Psychopharmacol 2010"},{"issue":"2","key":"10.1007\/s13311-017-0531-1_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/0269881106060513","article-title":"The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans","volume":"20","author":"Huxster","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0531-1_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2004.02.008","article-title":"Residual neuropsychological effects of illicit 3,4- methelenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs","volume":"75","author":"Halpern","year":"2004","journal-title":"Drug Alcohol Dependency"},{"key":"10.1007\/s13311-017-0531-1_bib32","article-title":"Effects of MDMA on 5-HT uptake sites using PET and [11C]-McN5652 in humans. Data presented at 2000 conference of the German Society for Psychiatry, Psychotherapy and Neuromedicine [Deutsche Gesellschaft f\u00fcr psychiatrie","author":"Vollenweider","year":"2000","journal-title":"Psychotherapie und Nervenheilkunde"},{"issue":"4","key":"10.1007\/s13311-017-0531-1_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","article-title":"Subjective reports of the effects of MDMA in a clinical setting","volume":"18","author":"Greer","year":"1986","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"10.1007\/s13311-017-0531-1_bib34","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1007\/s13311-017-0531-1_bib35","first-page":"57","article-title":"Using MDMA in psychotherapy","volume":"2","author":"Greer","year":"1985","journal-title":"Advances"},{"key":"10.1007\/s13311-017-0531-1_bib36","series-title":"Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA","first-page":"21","article-title":"The therapeutic use of MDMA","author":"Greer","year":"1990"},{"key":"10.1007\/s13311-017-0531-1_bib37","unstructured":"Gasser, P. (1995) Psycholytic Therapy with MDMA and LSD in Switzerland. Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS - Volume 5 Number 3 Winter 1994-95 - pp. 3-7"},{"key":"10.1007\/s13311-017-0531-1_bib38","article-title":"Underground LSD, MDMA and 2-CB-assisted Individual and Group Psychotherapy in Zurich: Outcomes, Implications and Commentary","author":"Sessa","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1007\/s13311-017-0531-1_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1177\/0269881112456611","article-title":"Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependence after 3,4-methylenedioxymeth- amphetamine-assisted psychotherapy: a prospective long-term follow- up study","volume":"27","author":"Mithoefer","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1007\/s13311-017-0531-1_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"Pilot study of MDMA-assisted psychotherapy for treatment-resistant PTSD","volume":"27","author":"Oehen","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"9","key":"10.1007\/s13311-017-0531-1_bib41","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0269881113495119","article-title":"MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder","volume":"s27","author":"Chabrol","year":"2013","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1007\/s13311-017-0531-1_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot Study of Psilocybin Treatment for Anxiety in Advanced-stage Cancer Patients","volume":"68","author":"Grob","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s13311-017-0531-1_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0091-3057(92)90645-V","article-title":"Attenuation of alcohol consumption by MDMA (Ecstasy) in two strains of alcohol-preferring rats","volume":"43","author":"Rezvani","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1007\/s13311-017-0531-1_bib44","doi-asserted-by":"crossref","DOI":"10.2174\/18744737112059990005","article-title":"Can MDMA play a role in the treatment of substance abuse?","author":"Jerome","year":"2013","journal-title":"Curr Drug Abuse Rev"},{"key":"10.1007\/s13311-017-0531-1_bib45","article-title":"The Secret Chief Revealed: Conversations with a pioneer of the underground therapy movement","author":"Stolaroff","year":"2004","journal-title":"Multidisciplinary Association for Psychedelic Studies"},{"issue":"4","key":"10.1007\/s13311-017-0531-1_bib46","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/08897070903250027","article-title":"Mindfulness-based therapies for substance use disorders: part 1 (editorial)","volume":"30","author":"Marcus","year":"2009","journal-title":"Substance Abuse"},{"key":"10.1007\/s13311-017-0531-1_bib47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-0-387-77725-2_13","article-title":"Mindfulness and addiction","volume":"18","author":"Hsu","year":"2008","journal-title":"Recent Developments in Alcoholism"},{"issue":"3","key":"10.1007\/s13311-017-0531-1_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jclp.20237","article-title":"Mechanisms of mindfulness","volume":"62","author":"Shapiro","year":"2006","journal-title":"J Clin Psychol"},{"issue":"3","key":"10.1007\/s13311-017-0531-1_bib49","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"(2015) Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"J Psychopharmacol"},{"issue":"11","key":"10.1007\/s13311-017-0531-1_bib50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0531-1_bib51","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research'","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J Psychoactive Drugs"},{"issue":"3","key":"10.1007\/s13311-017-0531-1_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/02791072.1991.10471587","article-title":"New age seekers: MDMA as an adjunct to spiritual pursuit","volume":"23","author":"Watson","year":"1991","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"10.1007\/s13311-017-0531-1_bib53","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/0269881106060764","article-title":"The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy","volume":"20","author":"Sumnall","year":"2006","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-017-0531-1_bib54","unstructured":"Office of National Statistics (ONS) (2014) \u2013 Alcohol Related Deaths in the United Kingdom: Registered in 2014."},{"key":"10.1007\/s13311-017-0531-1_bib55","unstructured":"Health and Social Care Information Centre (HSCIC) (2016) Statistics on Smoking: England, 2016 - Health and social care."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-017-0531-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923014526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-017-0531-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:58:22Z","timestamp":1761807502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923014526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1878747923014526"],"URL":"https:\/\/doi.org\/10.1007\/s13311-017-0531-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-017-0531-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}